This clinical trial is focused on studying treatments for Stage IV Colorectal Cancer, specifically in patients with a condition known as Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR). These are specific types of genetic changes in cancer cells that can affect how the cancer grows and responds to treatment. The study will explore the effectiveness of several treatments, including a combination of drugs called MK-1308A (which includes quavonlimab and pembrolizumab), as well as other treatments like MK-4280A, MK-7684A, and MK-4830 combined with pembrolizumab. Pembrolizumab is also being tested on its own.
The purpose of the study is to compare how well these treatments work in shrinking tumors and improving patient outcomes. Participants will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will be conducted over a period of time, and participants will be monitored to see how their cancer responds to the treatment. The study will also look at how long the response lasts, how long patients live without the cancer getting worse, and overall survival rates.
Throughout the study, the safety of the treatments will be closely monitored, and any side effects will be recorded. The study aims to provide valuable information on the effectiveness of these treatments for patients with this specific type of colorectal cancer, potentially leading to better treatment options in the future.



Belgium
Denmark
Estonia
France
Germany
Greece
Hungary
Italy
Lithuania
Poland
Romania
Spain
The Netherlands